The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with unresectable biliary tract cancers (BTCs).

Authors

Zhifang Li

Department of Bio-therapeutic, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China

Zhifang Li , Meixia Chen , Qianyi Ming , Yan Zhang , Kaichao Feng , Qian Mei , Yang Liu , Weidong Han

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

The interim analysis of a single-arm, open-label, phase II study investigating ALLEN regimen (durvalumab plus albumin paclitaxel and lenvatinib) in patients with metastatic pancreatic cancer (mPC).

First Author: Meixia Chen

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.

First Author: Konrad Friedrich Klinghammer

insert_chart_outlined

Poster

2017 Gastrointestinal Cancers Symposium

bookmark_border

Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC).

First Author: Chigusa Morizane

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

First Author: YunJung Kim